Please assess the completion status of the following clinical trial:

Trial Title: A Study to Establish the Efficacy of QBX258 in Patients With Moderate to Severe Asthma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with atopic asthma \>1 year duration diagnosed according to the GINA guidelines.~* Subjects must weigh at least 50 kg to participate in the study, and must have a body mass index (BMI) within the range of 18 - 39 kg/m2.~* Asthma which is not adequately controlled on current treatment, as demonstrated by an Asthma Control Questionnaire (ACQ) score of \> 1.5.~* FEV1 40 to 90% of predicted.~Exclusion Criteria:~* Diagnosed with COPD as defined by the GOLD guidelines~* Subjects who have had a respiratory tract infection within 4 weeks prior to screening.~* Women of child-bearing potential must use highly effective methods of contraception during dosing and for at least 18 weeks after last study drug administration

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- QBX258 (Type: EXPERIMENTAL): Participants received QBX258 intravenous (iv) infusion every 4 weeks for up to 4 doses total.
- Placebo (Type: PLACEBO_COMPARATOR): Participants received placebo to QBX258 iv infusion every 4 weeks for up to 4 doses total.

Based on this trial design, predict the completion outcome and termination type (if applicable).